Daniella Beckman Sells 4,284 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman sold 4,284 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total transaction of $12,809.16. Following the sale, the chief financial officer now owns 154,232 shares in the company, valued at approximately $461,153.68. The trade was a 2.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Tango Therapeutics Trading Down 7.1 %

Shares of TNGX stock opened at $3.03 on Friday. The stock has a market capitalization of $325.48 million, a price-to-earnings ratio of -2.57 and a beta of 0.80. Tango Therapeutics, Inc. has a 12-month low of $2.59 and a 12-month high of $12.80. The stock’s 50-day moving average price is $3.12 and its 200-day moving average price is $6.10.

Wall Street Analysts Forecast Growth

TNGX has been the topic of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a research report on Thursday, December 5th. Guggenheim decreased their price target on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Tango Therapeutics in a research note on Friday, November 8th. Finally, B. Riley decreased their target price on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics presently has an average rating of “Buy” and an average target price of $13.14.

Institutional Trading of Tango Therapeutics

Large investors have recently added to or reduced their stakes in the company. State Street Corp boosted its position in shares of Tango Therapeutics by 26.8% during the 3rd quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after acquiring an additional 489,949 shares during the last quarter. Geode Capital Management LLC raised its stake in Tango Therapeutics by 11.6% during the third quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock valued at $10,538,000 after purchasing an additional 142,710 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Tango Therapeutics by 5.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,429 shares of the company’s stock valued at $1,586,000 after purchasing an additional 26,192 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Tango Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock worth $2,882,000 after buying an additional 100,257 shares in the last quarter. Finally, Congress Asset Management Co. increased its holdings in shares of Tango Therapeutics by 9.0% in the 4th quarter. Congress Asset Management Co. now owns 227,989 shares of the company’s stock worth $704,000 after buying an additional 18,919 shares during the last quarter. Institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.